Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Fundamentals
Mkt Cap
$7.92B
Volume
-
52W High
$160.81
52W Low
$77.00
PE Ratio
25.71
Avg. Volume
742,676.03
EPS (Annual)
-$2.05
P/B
7.30
Rev/Employee
$348,606.06
Earnings
Nov 05
42
Bearish Sentiment
How do you feel about PTGX?
shoc24
$PTGX is ranked #6 in healthcare quality with a score of 90. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
Merlintrader
$PTGX — Four November bank conferences.
Information only — not investment advice.
More details in our hub.
Link your Stocktwits account
Ask your agent for live sentiment, watchers, trending tickers, and news.